ArticleScientific reports2025
Development and evaluation of the rivaroxaban loaded nanostructured lipid carriers for improved oral bioavailability and safety.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanocarrier Systems for Plant-Derived Bioactives: Design, Biosafety, and Translational Challenges.Pharmaceutics · 2026Review
- Enhancement of the Solubility and Dissolution Profile of Rivaroxaban by the Antisolvent Precipitation Technique: A Promising Approach.Polymers · 2026Article
- The Role and Potential of Nanotechnology in Improving Solubility and Enhancing Bioavailability.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A recent surge in deep vein thrombosis (DVT) has urged researchers to find potential candidates and new ways of drug delivery to treat the condition. Rivaroxaban (RIVA) is one of the active pharmaceutical agents used to treat DVT due to its unorthodox Xa-inhibiting therapeutic efficacy. However, its poor solubility and toxicity have restricted its therapeutic use. Herein, we prepared RIVA-NLCs to improve the biopharmaceutical performance of the drug. RIVA-NLCs were prepared using high-pressure homogenization and were evaluated based on particle size, zeta potential, polydispersity index, and entrapment efficiency. Differential scanning calorimetry (DSC), X-ray diffractometry (XRD), in vitro release, and in vivo pharmacokinetics studies were performed and compared with the pure drug. Additionally, toxicity studies and prothrombin time assessments were analyzed using cell viability and hemolysis assays. RIVA-NLCs demonstrated optimum particle properties with a particle size of 129.6 nm, zeta potential of -29.41 mV, polydispersity index of 0.012, and suitable entrapment efficiency of 95.7%. DSC and XRD respectively showed thermal stability and the amorphous nature of RIVA in NLCs. Moreover, a significantly improved release of RIVA was observed from the RIVA-NLCs compared to the pure drug at all the time periods and an overall improved release (6-folds) was observed in 24 h. Similarly, a 9.01-fold improved bioavailability of RIVA was detected in the RIVA-NLCs when compared with the pure drug. More importantly, the maximum concentration (Cmax) and area under the curve (AUC) of RIVA-NLCs were found 6344 ± 456 ng/mL and 19,367.43 ± 3148.12 ng.h/mL, that were significantly improved as as compared to RIVA suspension. It was concluded that NLCs have the potential to improve the dissolution, anticoagulant properties, and bioavailability of RIVA, as demonstrated in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.